Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration

International Journal of Ophthalmology

Volumn 4, Issue 1, 2011, Pages 85-88

  Feng, Xue Feng ^a   Constable, Ian J ^b   McAllister, Ian L ^b   Isaacs, Timothy ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Choroidal neovascularization; Ranibizumab

Indexed keywords

EID: 84894646354     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2011.01.20     Document Type: Article

References (14)

1. Wang JJ, Rochtchina E, Lee AJ, Chia EM, Smith W, Cumming RG, Mitchell P. Ten year incidence and progression of age-related maculopathy: the blue mountains eye study. Ophthalmology. 2007;114(1):92-98
2. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-262
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-143
4. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432- 1444.
5. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choriodal neovascularization secondary to age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol. 2007;245(1):68- 73
6. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145(2):249-256
7. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye. 2008;22(1):82-86
8. Feng X, Xiao J, Longville B, Tan AX, Wu XN, Cooper MN, McAllister IL, Isaacs T, Palmer LJ, Constable IJ. Complement factor H Y 402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology. 2009;116(10):1908-1912
9. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal Bevacizumab and Ranibizumab for age-related macular degeneration. A multicenter, retrospective study. Ophthalmology. 2010;117(2):298-302
10. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008;12(16):iii-2008;12(16):3-5+9-201
11. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27(4):439-444
12. Falkenstein IA, Cochran DE, Azen SP, Dustin L, Tammewar AM, Kozak I, Freeman WR. Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. Ophthalmology. 2008;115(2):319-323
13. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246- 252
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372